Precision Science Applied to the Biology of Health and Disease
Supported by Peer-Reviewed Research
Quanterix’ proprietary Simoa® technology is supported by over 1,000 peer-reviewed publications, covering all of our platforms and therapeutic areas.
Simoa® Assays by the Numbers
Quanterix’ Simoa® technology is changing the way in which the biology of health and disease is studied by giving researchers the ability to closely examine critical biomarkers.
In doing so, this game-changing technology enables the development of methods providing much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come.
Total Biomarker Assays
The ability to detect oncology biomarkers at ultra-low levels has the potential to enable new options for diagnostics and treatment in cancer research. Simoa® assays have the potential to be used to monitor cancer risk, identify early-stage cancers and discriminate between benign and malignant cells. Simoa biomarkers also have the potential to be used prognostically to predict disease outcome, predict progression-free survival and monitor reoccurrence, and to be used to monitor sensitivity to therapy and to aid in treatment decisions.see related assays
The ability to detect neurological biomarkers at ultra-low levels, which have traditionally only been detectable in cerebrospinal fluid, has the potential to transform the way brain injuries and diseases are diagnosed.
Simoa® assays can detect neurological biomarkers, such as Neurofilament Light (NfL),Tau, GFAP and several otohers associated with brain injury and disease. With Simoa, these informative markers can be detected at much earlier stages, in blood, serum or plasma, enabling better understanding of the long-term effects and disease pathology without invasive measures.
Quanterix has a strategic focus in neurodegeneration, neuroinflammation, traumatic brain injuries (TBI) and multiple sclerosis (MS) and is working with a rapidly growing network of academic researchers & pharmaceutical and biotech partners to drive advancements in head health research.
Simoa® assays can measure inflammatory and anti-inflammatory molecules in serum and plasma with unprecedented sensitivity enabling new discoveries into the role of inflammation in the biology of health and disease.see related assays
The ability to detect cardiac biomarkers at ultra-low levels is advancing the future of heart health. Simoa® assays have the potential to detect cardiac biomarkers, which are instrumental for predicting major adverse cardiovascular events, development of heart failure or transition to end-stage kidney disease, earlier than ever before. Further, the ability to detect minute changes in these biomarkers could enable the identification of at-risk patients earlier in their disease progression to guide more personalized, preventive care.see related assays
The ability to detect infectious disease biomarkers before the onset of an immune response, while a virus is most contagious and multiplying rapidly, is critical for controlling the spread of disease. Infectious disease is one of the hottest areas of research today and researchers continue to seek ways to detect and diagnose infections earlier and more accurately. Simoa® assays have the potential to have a significant impact in reducing the spread of the disease by making early stage detection more widely available.see related assays